S100B and melanoma: Several attempts have been made to develop small-molecule inhibitors (e.g., pentamidine) that inhibit molecular interactions between the Ca2+-S100B apoprotein and its binding proteins [12]; however, the small-molecule inhibitors, as well as siRNA-mediated knockdown, of S100B resulted in only transient restriction of melanoma cell growth.